TIDMMXCT TIDMTTM

RNS Number : 0074N

MaxCyte, Inc.

27 May 2022

Notice of AGM

GAITHERSBURG, MD, May 27, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), have been circulated to Shareholders.

The AGM will be held on Wednesday, June 29, 2022 at 11:00 a.m. Eastern Time at 21 Firstfield Road, Suite 202, Gaithersburg, Maryland.

These documents are also available in electronic form on the Company's website: www.maxcyte.com

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation(R) platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT(TM) platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx(TM), STx(TM) GTx(TM) and VLx(TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

 
 US IR Adviser                                    +1 415-937-5400 
  Gilmartin Group                                  ir@maxcyte.com 
  David Deuchler, CFA 
 Nominated Adviser and Joint Corporate Broker 
  Panmure Gordon 
  Emma Earl / Freddy Crossley 
  Corporate Broking 
  Rupert Dearden                                  +44 (0)20 7886 2500 
                                                  +44 (0)203 709 5700 
   UK IR Adviser                                   maxcyte@consilium-comms.com 
   Consilium Strategic Communications 
   Mary-Jane Elliott 
   Chris Welsh 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOADXGDUDGDDGDL

(END) Dow Jones Newswires

May 27, 2022 02:01 ET (06:01 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Maxcyte Charts.
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Maxcyte Charts.